E. Eric Tokat is Co-President of Investment banking at Centerview Partners, a leading independent investment bank with offices in New York, San Francisco, Menlo Park, London and Paris.
Mr. Tokat has been critical in helping to build Centerview into a preeminent advisory firm and positioning it for continued success. He is also one of the founders of the Healthcare practice at Centerview.
Mr. Tokat has advised on many of the most important, industry-defining life sciences transactions over his career and has played an instrumental role in establishing Centerview’s Healthcare practice as the market leader in strategic advisory. Mr. Tokat has advised on more than 100 transactions over his career exceeding $500 billion in total deal value.
Mr. Tokat’s recent life sciences transactions in the last ten years include:
- 2024: $3bn sale of Morphosys to Novartis, $2.5bn sale of Fusion to AstraZeneca, $3bn sale of EyeBio to Merck, $2.2bn sale of Inhibrx to Sanofi with simultaneous spin off of Oncology assets into a new publicly-traded company, $1.25bn sale of Numab to J&J, $1bn sale of Proteologix to J&J, $1.75bn sale of Mariana Oncology to Novartis, $950M sale of Amolyt to AstraZeneca, sale of Cardior to Novo Nordisk, sale of Harpoon to Merck
- 2023: $11bn sale of Prometheus to Merck, $4bn sale of Rayzebio to BMS, $3.5bn sale of Chinook to Novartis, $3bn sale of Carmot to Roche, $2.9bn sale of ProventionBio to Sanofi, $2bn sale of BellusHealth to GSK, $1.8bn sale of Cincor to AstraZeneca, $1.5bn acquisition of Amryt by Chiesi, $1.4bn sale of Point to Lilly, $1.2bn sale of Gracell to AstraZeneca, $1.2bn sale of VectivBio to Ironwood, $1.2bn sale of Albireo to Ipsen, sale of Emergence to Lilly, sale of Inversago to Novo Nordisk, sale of Decibel to Regeneron, Pfizer’s sale of select rare disease assets to AstraZeneca, sale of LianBio’s Mevacampten China rights to BMS
- 2022: $12.5bn sale of Biohaven to Pfizer with simultaneous spin of Neuroscience assets into a new publicly traded company; Sale of Imago BioSciences to Merck for $1.35bn; Sale of Akouos to Lilly for up to $600M; Sale of Oyster Point Pharma to Viatris for up to $500M; Sale of MiroBio to Gilead for $405M; Sale of ReViral Therapeutics to Pfizer for $525M; Sale of DSJ Antibodies to Abbvie for $255M; Sale of Checkmate Pharmaceuticals to Regeneron for $250M; Sale of Tmunity to Kite Pharma/Gilead
- 2021: Sale of Amunix Pharmaceuticals to Sanofi for $1bn Upfront and $225mm in Milestones; $6.7bn acquisition of Arena Pharmaceuticals by Pfizer; $2.3bn sale of Trillium Therapeutics to Pfizer; Up to $2bn sale of Vividion Therapeutics to Bayer AG; $1.7bn sale of Constellation Pharmaceuticals to Morphosys AG; $1.9bn sale of Pandion Therapeutics to Merck; $4.6bn sale of Cantel Medical to Steris; Sale of Lengo Therapeutics to Blueprint Medicines for up to $465M; Sale of Sanifit to Vifor Pharma for up to €375M; Pfizer’s spin out of select Autoimmune assets and creation of Priovant; $200M investment in Immunovant by Roivant
- 2020: $1bn sale of Prevail Therapeutics to Eli Lilly; $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
- 2019: ArQule's $2.7bn sale to Merck; Synthorx's $2.5bn sale to Sanofi; Achillion's up to $1.2bn sale to Alexion; Ra Pharma's $2.5bn sale to UCB S.A., Exact Sciences’ $2.8bn acquisition of Genomic Health; Peloton Therapeutics’ up to $2.2bn sale to Merck; Spark Therapeutics’ $4.8bn sale to Roche; Ipsen’s up to $1.3bn acquisition of Clementia Pharmaceuticals
- 2018: Merck’s €3.25bn acquisition of Antellia; Syntimmune’s up to $1.2bn sale to Alexion; Pfizer’s consumer JV with GSK; Pfizer’s spin out of CAR-T assets and creation of Allogene; Pfizer’s spin out of Neuroscience assets and creation of Cerevel Therapeutics; Synergy Pharmaceutical’s sale to Bausch Health
- 2017: Kite Pharma’s $12bn sale to Gilead; Valeant’s $1bn sale of Dendreon to Sanpower Group; China Regenerative Medicine’s acquisition of Obagi Medical from Valeant
- 2016: Pfizer’s $14bn acquisition of Medivation and $5bn acquisition of Anacor; Raptor’s $1bn sale to Horizon; Mylan’s $10bn acquisition of Meda
- 2015: Salix’s $16bn sale to Valeant; Dyax’s $6bn sale to Shire; Achillion's up to $1bn WW HCV collaboration with and $225m equity investment by J&J; Dendreon’s sale to Valeant
Mr. Tokat serves on a number of not-for-profit boards, including: a trustee at the Brookings Institution, a member of the Board of Advisors at the IRC (International Rescue Committee), a member of the Board of Advisors at Columbia University Irving Medical Center and Vagelos College of Physicians and Surgeons, as well as a member of the Board of Advisors of Columbia University School of International and Public Affairs. He is also a member of the Council on Foreign Relations.
Mr. Tokat received his BA from Bogazici University and MIA from Columbia University.